Pricing Log in Create free account
Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue
+50.1%
EPS
+147.3%
Free cash flow
+53.5%
Total debt
+0.45%

Quarter to September 2026, against a year earlier

394.41 5.69 −1.42%
Market cap
$9.3B
P/E
0.0×
Fwd P/E
−68.8×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. 10-Q filed May 6, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 9:04 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov